Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
GKOSALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos’ 2025 NDA labeling supplement application, and re
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
GKOSALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a major milestone in the company’s commitment to strengthening U.S. manufacturing, creating high-quality j
Glaukos Announces Participation in Wells Fargo Healthcare Conference
GKOSALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors
Morgan Stanley Maintains Underweight on Glaukos, Lowers Price Target to $72
GKOSWhat 11 Analyst Ratings Have To Say About Glaukos
GKOSStephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115
GKOSThis Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
GKOSStifel Maintains Buy on Glaukos, Lowers Price Target to $115
GKOSTruist Securities Reiterates Buy on Glaukos, Lowers Price Target to $135
GKOSWells Fargo Downgrades Glaukos to Equal-Weight, Lowers Price Target to $86
GKOSNeedham Maintains Buy on Glaukos, Lowers Price Target to $115
GKOSGlaukos Affirms FY2025 Sales Guidance of $475.00M-$485.00M vs $480.63M Est
GKOSGlaukos Q1 Adj. EPS $(0.22) Beats $(0.35) Estimate, Sales $106.66M Beat $102.50M Estimate
GKOSForecasting The Future: 7 Analyst Projections For Glaukos
GKOSMizuho Maintains Outperform on Glaukos, Lowers Price Target to $175
GKOSPiper Sandler Maintains Overweight on Glaukos, Lowers Price Target to $165
GKOSTruist Securities Maintains Buy on Glaukos, Lowers Price Target to $140
GKOSHere's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
GKOSTopcon Healthcare, RadiusXR, And Glaukos Announced A New Collaboration And The Launch Of RadiusXR's New Wearable Vision Testing Platform, Inspire
GKOSHere's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
GKOSFDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
GKOSGlaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Glaukos Secures FDA Acceptance Of NDA Submission For Epioxa
GKOSGlaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
GKOSGlaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $160
GKOSNeedham Maintains Buy on Glaukos, Raises Price Target to $176
GKOSGlaukos Sees FY25 Revenue $475M-$485M
GKOSGlaukos Q4 2024 Adj. EPS $(0.40) Misses $(0.38) Estimate, Sales $105.500M Beat $100.491M Estimate
GKOSMizuho Upgrades Glaukos to Outperform, Raises Price Target to $200
GKOSPeering Into Glaukos's Recent Short Interest
GKOSGlaukos Announces Clinical Updates For iDose Sustained-Release Procedural Pharmaceutical Platform
GKOSShort Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
GKOSTransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
GKOSGlaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
GKOSGlaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.
JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $145
GKOSWells Fargo Maintains Overweight on Glaukos, Raises Price Target to $145
GKOSGlaukos Sees 2024 Net Sales $377M-$379M
GKOSGlaukos Q3 2024 Adj. EPS $(0.28) Beats $(0.48) Estimate, Sales $96.700M Beat $91.494M Estimate
GKOSDeep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
GKOSCitigroup Maintains Buy on Glaukos, Raises Price Target to $130
GKOSGlaukos Sees FY22 Sales $270M-$275M vs $270.49M Est.
GKOSGlaukos Q1 Adj. EPS $(0.38) Beats $(0.50) Estimate, Sales $67.70M Beat $60.85M Estimate
GKOS